208 related articles for article (PubMed ID: 29315345)
1. Identification and functional analysis of SOX10 phosphorylation sites in melanoma.
Cronin JC; Loftus SK; Baxter LL; Swatkoski S; Gucek M; Pavan WJ
PLoS One; 2018; 13(1):e0190834. PubMed ID: 29315345
[TBL] [Abstract][Full Text] [Related]
2. MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells.
Fufa TD; Baxter LL; Wedel JC; Gildea DE; ; Loftus SK; Pavan WJ
Epigenetics Chromatin; 2019 Aug; 12(1):50. PubMed ID: 31399133
[TBL] [Abstract][Full Text] [Related]
3. Genomic analysis reveals distinct mechanisms and functional classes of SOX10-regulated genes in melanocytes.
Fufa TD; Harris ML; Watkins-Chow DE; Levy D; Gorkin DU; Gildea DE; Song L; Safi A; Crawford GE; Sviderskaya EV; Bennett DC; Mccallion AS; Loftus SK; Pavan WJ
Hum Mol Genet; 2015 Oct; 24(19):5433-50. PubMed ID: 26206884
[TBL] [Abstract][Full Text] [Related]
4. Sox10 regulates skin melanocyte proliferation by activating the DNA replication licensing factor MCM5.
Su Z; Zheng X; Zhang X; Wang Y; Zhu S; Lu F; Qu J; Hou L
J Dermatol Sci; 2017 Mar; 85(3):216-225. PubMed ID: 27955842
[TBL] [Abstract][Full Text] [Related]
5. UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling.
Dikshit A; Jin YJ; Degan S; Hwang J; Foster MW; Li CY; Zhang JY
Cancer Res; 2018 Nov; 78(22):6462-6472. PubMed ID: 30224375
[TBL] [Abstract][Full Text] [Related]
6. SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects.
Rosenbaum SR; Tiago M; Caksa S; Capparelli C; Purwin TJ; Kumar G; Glasheen M; Pomante D; Kotas D; Chervoneva I; Aplin AE
Cell Rep; 2021 Dec; 37(10):110085. PubMed ID: 34879275
[TBL] [Abstract][Full Text] [Related]
7. The myelin protein PMP2 is regulated by SOX10 and drives melanoma cell invasion.
Graf SA; Heppt MV; Wessely A; Krebs S; Kammerbauer C; Hornig E; Strieder A; Blum H; Bosserhoff AK; Berking C
Pigment Cell Melanoma Res; 2019 May; 32(3):424-434. PubMed ID: 30506895
[TBL] [Abstract][Full Text] [Related]
8. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma.
Capparelli C; Purwin TJ; Glasheen M; Caksa S; Tiago M; Wilski N; Pomante D; Rosenbaum S; Nguyen MQ; Cai W; Franco-Barraza J; Zheng R; Kumar G; Chervoneva I; Shimada A; Rebecca VW; Snook AE; Hookim K; Xu X; Cukierman E; Herlyn M; Aplin AE
Nat Commun; 2022 Mar; 13(1):1381. PubMed ID: 35296667
[TBL] [Abstract][Full Text] [Related]
9. Stringent comparative sequence analysis reveals SOX10 as a putative inhibitor of glial cell differentiation.
Gopinath C; Law WD; Rodríguez-Molina JF; Prasad AB; Song L; Crawford GE; Mullikin JC; Svaren J; Antonellis A
BMC Genomics; 2016 Nov; 17(1):887. PubMed ID: 27821050
[TBL] [Abstract][Full Text] [Related]
10. Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth.
Uka R; Britschgi C; Krättli A; Matter C; Mihic D; Okoniewski MJ; Gualandi M; Stupp R; Cinelli P; Dummer R; Levesque MP; Shakhova O
Oncogene; 2020 May; 39(20):4132-4154. PubMed ID: 32238882
[TBL] [Abstract][Full Text] [Related]
11. Sox10 controls migration of B16F10 melanoma cells through multiple regulatory target genes.
Seong I; Min HJ; Lee JH; Yeo CY; Kang DM; Oh ES; Hwang ES; Kim J
PLoS One; 2012; 7(2):e31477. PubMed ID: 22363655
[TBL] [Abstract][Full Text] [Related]
12. The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway.
Zheng Y; Sun Y; Liu Y; Zhang X; Li F; Li L; Wang J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2451-2458. PubMed ID: 29969627
[TBL] [Abstract][Full Text] [Related]
13. Regulation of SOX10 stability via ubiquitination-mediated degradation by Fbxw7α modulates melanoma cell migration.
Lv XB; Wu W; Tang X; Wu Y; Zhu Y; Liu Y; Cui X; Chu J; Hu P; Li J; Guo Q; Cai Z; Wu J; Hu K; Ouyang N
Oncotarget; 2015 Nov; 6(34):36370-82. PubMed ID: 26461473
[TBL] [Abstract][Full Text] [Related]
14. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma.
Shakhova O; Zingg D; Schaefer SM; Hari L; Civenni G; Blunschi J; Claudinot S; Okoniewski M; Beermann F; Mihic-Probst D; Moch H; Wegner M; Dummer R; Barrandon Y; Cinelli P; Sommer L
Nat Cell Biol; 2012 Aug; 14(8):882-90. PubMed ID: 22772081
[TBL] [Abstract][Full Text] [Related]
15. Subnuclear re-localization of SOX10 and p54NRB correlates with a unique neurological phenotype associated with SOX10 missense mutations.
Chaoui A; Kavo A; Baral V; Watanabe Y; Lecerf L; Colley A; Mendoza-Londono R; Pingault V; Bondurand N
Hum Mol Genet; 2015 Sep; 24(17):4933-47. PubMed ID: 26060192
[TBL] [Abstract][Full Text] [Related]
16. SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis.
Yokoyama S; Takahashi A; Kikuchi R; Nishibu S; Lo JA; Hejna M; Moon WM; Kato S; Zhou Y; Hodi FS; Song JS; Sakurai H; Fisher DE; Hayakawa Y
Cancer Res; 2021 Dec; 81(24):6131-6141. PubMed ID: 34728538
[TBL] [Abstract][Full Text] [Related]
17. PAX3 and SOX10 activate MET receptor expression in melanoma.
Mascarenhas JB; Littlejohn EL; Wolsky RJ; Young KP; Nelson M; Salgia R; Lang D
Pigment Cell Melanoma Res; 2010 Apr; 23(2):225-37. PubMed ID: 20067553
[TBL] [Abstract][Full Text] [Related]
18. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses.
Shin J; Vincent JG; Cuda JD; Xu H; Kang S; Kim J; Taube JM
J Am Acad Dermatol; 2012 Oct; 67(4):717-26. PubMed ID: 22325460
[TBL] [Abstract][Full Text] [Related]
19. SOX10/keratin dual-color immunohistochemistry: An effective first-line test for the workup of epithelioid malignant neoplasms in FNA and small biopsy specimens.
Mito JK; Conner JR; Hornick JL; Cibas ES; Qian X
Cancer Cytopathol; 2018 Mar; 126(3):179-189. PubMed ID: 29385322
[TBL] [Abstract][Full Text] [Related]
20. Sox10 and S100 in the diagnosis of soft-tissue neoplasms.
Karamchandani JR; Nielsen TO; van de Rijn M; West RB
Appl Immunohistochem Mol Morphol; 2012 Oct; 20(5):445-50. PubMed ID: 22495377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
